Compare KN & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | SNDX |
|---|---|---|
| Founded | 1946 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2016 |
| Metric | KN | SNDX |
|---|---|---|
| Price | $22.52 | $20.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $22.33 | ★ $36.92 |
| AVG Volume (30 Days) | 657.5K | ★ 2.1M |
| Earning Date | 10-23-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $573,500,000.00 | $111,304,000.00 |
| Revenue This Year | $9.26 | $620.14 |
| Revenue Next Year | $5.87 | $115.42 |
| P/E Ratio | $47.94 | ★ N/A |
| Revenue Growth | 4.24 | ★ 595.65 |
| 52 Week Low | $12.19 | $8.58 |
| 52 Week High | $24.54 | $21.22 |
| Indicator | KN | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 67.42 |
| Support Level | $23.19 | $20.00 |
| Resistance Level | $24.18 | $21.22 |
| Average True Range (ATR) | 0.61 | 0.93 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 28.76 | 85.90 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.